Pricing Log in Create free account
Saturday 17 October 2026 Export NSPR’s income statement to Excel — free account

InspireMD, Inc.

NSPR Healthcare Medical Devices

InspireMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 28.1% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 34.6% and free cash flow fell 26.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

0.46 0.02 −4.17%
Market cap
$22.3M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
5/9
Altman Z
−2.61
Beneish M
−3.55
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.43
Total sells 0.10
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 4 — — — — 7 — — — — —
Sell — — 1 — — — — — — — — —
Insider Ownership 60.94%

Capital & Financial Ratios $m

Market Cap 22.34
Revenue 10.84
Net Income (52.48)
Free Cash Flow (42.45)
Net Debt (30.42)
Current Ratio 3.80 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (2.52) (negative: loss-making)
P/S ratio 3.59
P/B ratio 1.24
Past 5Y EPS Growth —
This Y EPS Growth 19.30% (at or above 15%: strong)
Next Y EPS Growth 21.20% (at or above 15%: strong)
Next Y revenue growth 9.13%
Next 5Y EPS Growth 5.98%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.1×, against a ten-year median of 0.9×; over the ten years it ranged from −3.1× in 2021 to 17.9× in 2025.
P/S against its own 10 years 50.53%
10-year low 10-year high
P/B against its own 10 years 59.96%
10-year low 10-year high
EV/Sales against its own 10 years 34.61%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2018 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 39 35 54 30
Receivables 2 2 3 2
Inventory 2 3 3 3
Other — — — —
44 41 61 37
2023 2024 2025 Q'26
Payables 6 8 11 10
ST’ Debt — — — —
Other — — — —
6 8 11 10

Compound Annual Growth %

10y 5y 3y
Sales 14.54% 29.29% 20.19%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 35.33% 46.96%

Revenue $m

Mar Jun Sep Dec Year
’26 3 2 — — —
’25 2 2 3 3 9
’24 2 2 2 2 7
’23 1 2 2 2 6
’22 1 2 1 1 5
’21 1 1 1 1 4
’20 1 0 1 0 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (11) — — —
’25 (9) (8) (9) (9) (35)
’24 (5) (4) (6) (7) (22)
’23 (5) (3) (4) (4) (16)
’22 (4) (3) (5) (3) (16)
’21 (4) (3) (4) (3) (13)
’20 (2) (1) (3) (2) (9)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (13) (11) — — —
’25 (9) (9) (9) (10) (37)
’24 (5) (5) (6) (7) (23)
’23 (5) (3) (4) (4) (17)
’22 (4) (3) (5) (3) (16)
’21 (4) (3) (4) (3) (14)
’20 (2) (1) (3) (2) (9)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.16) (0.17) — — —
’25 — (0.26) (0.17) (0.14) (0.76)
’24 (0.21) (0.22) (0.16) (0.19) (0.76)
’23 (0.53) (0.24) (0.15) (0.16) (0.82)
’22 (0.57) (0.59) (0.58) (0.60) (2.35)
’21 (0.53) (0.46) (0.53) (0.53) (2.03)
’20 (6.45) (3.00) (0.90) (1.50) (6.90)
Fiscal quarters ending in the months shown.
value withheld pending a data check

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 37,012.50 3,150.00 97.50 11.10 4.20 2.83 0.81 0.84 1.81 1.59

Analyst estimates 2026–2028

Powerpack
High 623,437.50 104,212.50 8,400.00 172.50 24.60 22.20 3.33 3.85 3.42 3.80
People
People Employees 34 36 43 48 48 52 56 66 86 127
Revenue/emp, $m 0.06 0.08 0.08 0.08 0.05 0.09 0.09 0.09 0.08 0.07
Income, $m
Income, $m Revenue 2 3 4 4 2 4 5 6 7 9
Gross margin, % 5.39 21.19 27.63 20.32 3.34 16.77 21.60 29.12 21.49 29.50
EBT (8) (8) (7) (10) (11) (15) (18) (20) (32) (49)
EBT margin, % (446.67) (304.64) (201.06) (269.17) (424.14) (330.88) (357.05) (319.92) (455.79) (542.63)
Net income (8) (8) (7) (10) (11) (15) (18) (20) (32) (49)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 18,940.00 5,522.00 116.92 26.69 1.64 0.61 0.66 0.26 0.17 0.14
Earnings (155,429.30) (26,221.89) (247.38) (71.96) (6.90) (2.03) (2.35) (0.82) (0.76) (0.76)
Cash flow (74,950.00) (16,262.00) (246.95) (70.37) (6.00) (1.80) (1.97) (0.67) (0.52) (0.55)
Capex (490.00) (516.00) (2.18) (2.04) (0.04) (0.05) (0.06) (0.02) (0.03) (0.03)
Free cash flow (75,440.00) (16,778.00) (249.12) (72.41) (6.05) (1.85) (2.03) (0.69) (0.55) (0.57)
Book value 40,450.00 5,454.00 284.51 38.62 8.04 4.56 2.21 1.63 0.86 0.86
Shares, m 0 0 0 0 2 7 8 24 42 64
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 3.27 0.62 1.03 0.61 3.10 4.94 1.40 10.60 15.73 12.75
P/B 1.53 0.63 0.42 0.42 0.63 0.66 0.42 1.66 3.06 2.07
EV/Sales 1.30 0.64 (0.53) 0.14 (0.46) (1.80) (1.31) 4.92 11.33 7.14
EV/FCF (0.33) (0.21) 0.25 (0.05) 0.12 0.60 0.42 (1.82) (3.41) (1.74)
Cash, $m
Cash, $m Operating cash flow (7) (8) (8) (10) (9) (13) (16) (16) (22) (35)
Capex 0 0 0 0 0 0 0 0 (1) (2)
Free cash flow (8) (8) (8) (10) (9) (14) (16) (17) (23) (37)
Balance, $m
Balance, $m Working capital 4 3 8 5 12 33 16 38 33 51
Total debt 3 — — 1 1 1 2 — — —
Net debt (5) (4) (9) (6) (13) (34) (18) (39) (35) (54)
Shareholders’ equity 4 3 9 5 12 34 17 40 36 55
Returns, %
Returns, % ROA (112.04) (167.92) (78.72) (90.58) (76.25) (51.90) (57.46) (55.10) (67.77) (83.96)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (2,764.51) (1,445.09) (3,132.20)
ROE (1,539.76) (384.76) (126.02) (141.95) (120.19) (65.29) (72.62) (70.01) (84.68) (106.88)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

InspireMD, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NSYS Nortech Systems Incorporated $29.5M 27.9× 17.5× +9.34% (above 0%: growing) −8.33% (below 0%: shrinking) −1,567.16% (below 0%: shrinking) 17.00% 1.86% Compare
ITOC iTonic Holdings Ltd. $29.3M — — — — — — — Compare
PMI Flag Ship Acquisition Corp $23.4M 0.5× — (loss-making) +38.62% (above 0%: growing) n/m +46.79% (above 0%: growing) 20.85% (156.70%) Compare
NSPR InspireMD, Inc. $22.3M — (loss-making) — (loss-making) −0.39% (below 0%: shrinking) n/m −26.00% (below 0%: shrinking) (43.70%) (815.64%)
ARAY Accuray Incorporated $20.8M — (loss-making) — (loss-making) −20.87% (below 0%: shrinking) n/m +117.83% (above 0%: growing) 35.22% 5.47% Compare
MODD Modular Medical, Inc. $20.5M — (loss-making) — — n/m −5.61% (below 0%: shrinking) 0.00% 0.00% Compare
PAVM PAVmed Inc. $19.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%) Compare
BDMD Baird Medical Investment Holdings Limited $19.2M — (loss-making) — — n/m −598.12% (below 0%: shrinking) — — Compare
LFWD Lifeward Ltd. $17.2M — (loss-making) — (loss-making) +15.71% (above 0%: growing) n/m −52.77% (below 0%: shrinking) 40.90% (62.69%) Compare
Median of peers $20.6M — — +15.71% — −52.77% 18.93% (31.34%)

All 149 Medical Devices stocks →

InspireMD, Inc. (NSPR) key facts

  • Strength: InspireMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 28.1% from fiscal 2024.
  • InspireMD, Inc. (NSPR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, NSPR traded at $0.46, a market capitalization of $22.3 million.
  • Return on equity was −106.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −2.61 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

InspireMD, Inc. (NSPR) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/NSPR · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com